Skip to main content
. 2017 Oct 11;12(10):e0177863. doi: 10.1371/journal.pone.0177863

Table 1. Immunization schema1.

Group
(n = 4)		 T #1
(t = 0)		 T #2
(t = 8w)		 T #3
(t = 16w)		 T #4
(t = 24w)		 T #5
(t = 40w)		 T#6
(t = 56w)
1
(T/F)		 DNA-T/F
(left)		 DNA-T/F
(left)		 MVA-T/F
(right)		 MVA-T/F
(right)		 MVA-T/F
(right)		 MVA-T/F
(right)
gp120-T/F
(left)
2
(D/L)		 DNA-T/F
(left)		 DNA-T/F
(left)		 MVA-T/F
(right)		 MVA53C
(right)		 MVA78C
(right)		 MVA100C
(right)
gp120-100C
(left)
3
(D/L+ gp120)		 DNA-T/F
(left)		 DNA-T/F
(left)		 MVA-T/F
(right)		 MVA53C
(right)		 MVA78C
(right)		 MVA100C
(right)
gp120-T/F
(left)		 gp120-53C
left)		 gp120-78C
(left)

1DNA (3 mg), MVA (1X108 TCID50) and gp120 protein (0.3 mg of protein in 0.6 mg of Alhydrogel) were delivered in 1 ml intramuscularly to the indicated thigh using a hypodermic needle and syringe.